Dec. 17, 2021

In this episode, Chiara Cremolini, MD, PhD, and Teresa Macarulla, MD, PhD, discuss the clinical data that inform how they select regorafenib and TAS-102 as later-line treatment for patients with mCRC, with topics including:

  • Transitioning from second- to third-line therapy
  • Factors in selecting among available therapies
  • Key predictors of improved outcomes with regorafenib vs TAS-102


Chiara Cremolini, MD, PhD
Medical Oncologist  
Unit of Medical Oncology 2  
Azienda Ospedaliero-Universitaria Pisana
Department of Translational Research and New Technologies in Medicine and Surgery
University of Pisa
Pisa, Italy 

Teresa Macarulla, MD, PhD
Medical Oncologist
Head, Gastrointestinal and Endocrine Tumors Unit  
Division of Medical Oncology
Vall d´Hebrón Institute of Oncology
Barcelona, Spain

Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Link to full program:

This episode is from CCO Oncology Podcast whose proprietor has full ownership and responsibility on its contents and artworks. It was shared using Castamatic, a podcast app for iPhone and iPad.